Chronic myeloid leukemia (CML) treatment in Istanbul, Turkey
Chronic myeloid leukemia is a blood cancer driven by the BCR-ABL1 fusion gene from the Philadelphia chromosome, and it is one of oncology’s great success stories: an oral targeted pill called a tyrosine kinase inhibitor — imatinib, dasatinib, nilotinib and others — controls most chronic-phase disease for many years, so care is largely outpatient and monitoring-driven rather than surgical. Regular BCR-ABL PCR blood tests track how deeply you respond and guide whether to switch TKIs, and stem cell transplant is now reserved for the few whose disease resists treatment. Istanbul hospitals offer this full pathway, often at JCI-accredited, state-authorized centers and well below Western-European prices. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
What chronic myeloid leukemia is
The U.S. National Cancer Institute describes chronic myeloid leukemia (CML) as a slowly progressing blood-and-bone-marrow cancer in which the body makes too many abnormal white blood cells. What sets CML apart is a single genetic driver: the Philadelphia chromosome, formed when parts of two chromosomes swap places and create the BCR-ABL1 fusion gene. That gene makes an abnormal protein that keeps telling the cells to keep growing, which is exactly the switch modern drugs are built to turn off.
The NCI describes three phases — chronic, accelerated and blast — and most people are diagnosed in the chronic phase, sometimes from a routine blood test before symptoms appear. Diagnosis rests on blood counts, a bone-marrow examination, and genetic tests that confirm the Philadelphia chromosome or the BCR-ABL1 gene. Those same molecular tests are then repeated over time to measure response. Browse the wider cancer types hub for related diagnoses.
Treatment options
The approaches the NCI lists for CML, and an honest note on each:
- Tyrosine kinase inhibitors (TKIs). The mainstay — imatinib, and later-generation dasatinib, nilotinib, bosutinib and ponatinib — are oral pills that block the BCR-ABL protein. Usually taken daily and long-term, they let most people with chronic-phase CML reach a deep, durable remission.
- Molecular monitoring (BCR-ABL PCR). Not a drug but the heart of CML care: periodic PCR blood tests measure how much BCR-ABL remains, showing whether a TKI is working and guiding whether to continue or switch. This monitoring is what makes CML largely outpatient rather than hospital-based.
- Allogeneic stem cell transplant. Once the main curative option, transplant is now reserved for the few whose disease resists TKIs or progresses. It is a major procedure with a matched-donor requirement, so it is weighed carefully against continued drug therapy.
- Managing the accelerated or blast phase. If CML advances beyond the chronic phase, treatment intensifies — higher-potency or different TKIs, chemotherapy, and transplant may be combined. Which applies is decided by your phase and molecular testing, not a template.
See how targeted therapy and bone marrow transplant work in general, or explore the whole treatments & technology hub. This is one subtype within the broader leukemia treatment overview.
What it costs
CML is unusual on cost, because the total is dominated by the long-term oral TKI drugitself rather than by surgery or long hospital stays — it is a daily pill taken for years, and generic versus later-generation branded TKIs differ widely in price. Added to that are the periodic BCR-ABL PCR molecular tests and clinic visits that guide the plan, and, in the rare cases that need it, transplant. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling specialists or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose hematology and stem-cell-transplant subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
CML is one subtype within the broader leukemia treatment in Turkey overview, which itself sits inside the cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your blood counts, bone-marrow and molecular results into a plain-language case file in your language before you decide whether to travel.
Related cancers
Check everything here — us included
Common questions
Can I get CML treatment in Turkey?
Yes. Istanbul hospitals provide the full chronic myeloid leukemia pathway the U.S. National Cancer Institute describes — daily oral tyrosine kinase inhibitors such as imatinib, dasatinib or nilotinib as the mainstay, regular BCR-ABL PCR blood monitoring to measure how deeply the disease is responding, switching to a different TKI if one stops working or is poorly tolerated, and allogeneic stem cell transplant kept in reserve for the few whose disease resists treatment or progresses. Because chronic-phase CML is largely controlled with a pill, care is mostly outpatient. Many centers hold JCI accreditation and Turkish Ministry of Health state authorization, both of which you can check yourself. The honest first step is a free case review of your blood and molecular reports.
How do TKIs like imatinib work in CML?
CML is driven by the BCR-ABL1 fusion gene, made when the Philadelphia chromosome joins parts of two chromosomes together. Per the NCI, that fusion produces an abnormal tyrosine kinase protein that keeps signalling the cell to divide. Tyrosine kinase inhibitors — imatinib, and later-generation dasatinib, nilotinib, bosutinib and ponatinib — block that protein, switching off the growth signal. Taken as a daily pill, they let most people with chronic-phase CML reach a deep, durable remission measured by molecular testing. If one TKI stops working or causes side effects, another can often be substituted. This is general information, not a treatment recommendation.
Will I need a stem cell transplant for CML?
Usually not. Before TKIs, allogeneic stem cell transplant was the main curative option for CML; today the NCI describes it as reserved mainly for people whose disease resists tyrosine kinase inhibitors or progresses to the accelerated or blast phase. Most people with chronic-phase CML are controlled for many years on a daily pill and never need a transplant. When transplant is considered, it is a major procedure with its own risks and a matched donor requirement, decided by a hematology team. A case review will tell you what your molecular response and phase do and don't yet establish about whether transplant is even on the table.
How much does CML treatment cost in Istanbul?
There is no single figure, and CML is unusual because the cost is dominated by the long-term oral TKI drug itself rather than by surgery or hospital stays — it is a daily pill taken for years, and generic versus later-generation branded TKIs differ widely in price. Added to that are the periodic BCR-ABL PCR molecular tests and clinic visits that guide the plan, and, in the rare cases that need it, transplant. Istanbul typically runs well below Western-European prices for the same protocol, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real written quote line by line. See the Turkey Oncology Price Index for current ranges.
Start with a free 72-hour case review
Send your blood counts, bone-marrow and molecular reports. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.